Radioactive beads aim to shrink untreatable liver tumors

NCT ID NCT06302400

Terminated Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early trial tested the safety and effectiveness of radioactive beads (Holmium-166 microspheres) in 4 adults with liver cancer that could not be removed by surgery or transplant. Participants first received a small scout dose to check for proper placement, then a personalized therapeutic dose. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Holmium-166 microspheres (radioactive beads)
What this could lead to: If successful, this could provide a new treatment option for liver cancer patients who cannot have surgery or transplant.
What could go wrong: This is a very early, small trial (only 4 participants) that was terminated, so results are limited. The treatment involves radiation, which can cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

Contacts and locations

Locations

Imperial College Healthcare NHS Trust

London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.